Something Weird Is Going On With Placebos

Summary

Placebos and “Real” Treatments

The speakers describe a placebo as a treatment without a known active pharmaceutical or biological ingredient, such as a sugar pill. They use verum for a treatment with known biological activity.

A treatment may still be considered active even when its precise mechanism is not fully understood, as with anesthesia.

Placebo Responses in Clinical Trials

A McGill University analysis by Tuttle and Toyama reportedly found that, in U.S. pain-relief trials, active drugs’ advantage over placebo narrowed from 27.3% in 1996 to 8.9% in 2013. The speakers stress that this does not mean painkillers necessarily became weaker; rather, the placebo response appeared to grow.

They also cite antidepressant trials in which placebo improved scores by about eight points on a depression scale, compared with about ten points for the best medications discussed. These figures are presented as averages, not as a claim that medication has no effect.

Why U.S. Trials Might Show a Stronger Trend

Tuttle and Toyama proposed two possible explanations, which the speakers say need more testing:

• U.S. clinical trials became longer, averaging about four weeks in 1996 versus twelve weeks in 2013.
• U.S. patients are exposed to pharmaceutical advertising, which may shape expectations about treatment.

How Expectations and Context May Influence Symptoms

Pain is described as an experience constructed by the brain from incoming information, rather than a simple, objective measure of bodily damage. The speakers outline two proposed explanations for placebo effects:

• Classical conditioning: Past experiences of feeling better after treatment can lead someone to feel better when receiving treatment again.
• Expectations and reassurance: Symptoms such as pain may help signal a need for care. Once a person feels that help is available, the brain may reduce the urgency of those symptoms.

The discussion suggests that expectation and the experience of being cared for can affect symptoms such as pain or distress, but cannot substitute for treatments that address physical causes. For example, a placebo does not kill bacteria in a wound or repair a broken bone.

Migraine Experiment

The speakers describe a Harvard Medical School study in which migraine patients received envelopes labelled as Maxalt, placebo, or unknown; a no-treatment group received no envelope. The actual contents did not always match the label: each envelope group had a 50% chance of containing Maxalt or a placebo.

The no-treatment group reported worsening pain on average, while the treated groups reported reductions. Active medication generally performed better, but among participants who actually received Maxalt, the best reported outcome was in those told they might or might not have received the drug. The proposed explanation is that uncertainty may lead people to monitor their symptoms more closely. The speakers present this as a hypothesis, not a settled mechanism.

Open-Label Placebos and Terminology

The discussion notes that placebos can sometimes have effects even when patients know they are receiving one. An openly disclosed placebo is not a nocebo. A nocebo is when negative expectations contribute to pain or other unwanted symptoms.

The subtitles appear to muddle these terms; knowing that a pill is inactive does not, by itself, make it a nocebo.

Ritual and Presentation

The speakers say that treatment context can influence reported effects. The same treatment may seem more effective when delivered by a clinician in a lab coat or by injection than when given as a simple tablet.

They also describe a demonstration in which people believed a flashlight-based device was a medical laser. The presentation and suggestion led some participants to report pain.

Stress, Self-Care, and the Limits of “Doing Something”

Feeling supported or taking steps such as exercising, meditating, changing diet, or socializing may reduce worry and affect how symptoms are experienced. The speakers suggest that reduced stress may allow the body to focus less on distress signals, while acknowledging that the biological mechanisms are not always clear.

They caution against assuming that more intervention is always better:

• They cite a long-term comparison of surgery, radiotherapy, and active monitoring for early-stage prostate cancer, reporting no survival difference among the groups in that study. Monitored patients could receive further treatment if the cancer became aggressive.
• They also describe South Korea’s thyroid-cancer screening program as increasing operations without improving survival, according to the account given.

These examples are used to distinguish careful monitoring and appropriate care from unnecessary intervention—not to suggest that cancer should be ignored.

Belief and Behavior Beyond Medicine

The speakers use the Tinker Bell effect for situations in which belief helps make an outcome real. They give school performance and self-efficacy as examples: confidence in a method or in one’s abilities may influence effort and results.

They contrast this with road safety: believing driving is very safe may encourage carelessness, while believing it is risky may make people more attentive.

They also discuss placebo-like controls—including some pedestrian-crossing buttons, elevator controls, thermostats, and sound-engineering sliders—that may provide a sense of control even when their practical effect is limited or absent.

Cancer Research Segment

The episode’s sponsor segment says that an ancient Egyptian papyrus contains an early written description of cancer and describes tumors being removed with a tool translated as a “fire drill.”

It also credits Cancer Research UK with supporting research into cancer-detection robots and medicines involving gut bacteria, and says its work helped double cancer survival rates in the UK over 50 years.

Researchers and Sources Mentioned

• Tuttle and Toyama, researchers at McGill University, associated with the analysis of placebo responses over time.
• Irene Tracey, described as a pain researcher at Oxford.
• Harvard Medical School, associated with the migraine study discussed; individual study researchers are not named.
• McGill University
• Cancer Research UK
• Mind Field, including episodes on suggestion and touch, referenced by Michael Stevens.